pharmaceuticals

Global Custom Market Research Reports Provider Company

phone

Alfa Wassermann SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Published Date: 11 Apr 2018
  • Number of Pages: 38
  • Category: Pharmaceuticals
  • Country: Italy
Summary

Alfa Wassermann SpA (Alfa Wassermann), a subsidiary of AlfaSigma SpA is a pharmaceutical company which produces and distributes drugs for human health. The company provides new discoveries in medicine, biology and genomics. Alfa Wassermann finds solutions for paradox treatment. The company offers self meditation products for sore throat, headaches, and muscle and joint pain treatments. It also provides antibiotics used for treatment of diseases such as vascular diseases, deep venous thrombosis and gastrointestinal tract diseases. Alfa Wassermann operates through its offices located in the US, the Netherlands, Mexico, France, Spain, Portugal, China, Poland, Romania, Tunisia and Slovakia. Alfa Wassermann is headquartered in Bologna, Italy.

Alfa Wassermann SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons To Buy


Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Publisher Name : GlobalData

3
List of Tables 4
List of Figures 4
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfa Wassermann SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alfa Wassermann SpA, Medical Devices Deals, 2012 to YTD 2018 10
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 13
Partnerships 15
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 15
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 16
European Institute of Oncology Enters Into Co-Development Agreement With Sigma Tau Industrie 17
Theravance Enters Into Co-Development Agreement With Alfa Wassermann For Velusetrag 18
a V.I. Pharma Enters into Distribution Agreement with Sigma-Tau for Eurartesim 19
Ezose Sciences Enters Into R&D Agreement With Sigma-Tau Industrie Farmaceutiche 20
Licensing Agreements 21
CVie Therapeutics to Enter into Licensing Agreement with RostaQuo 21
CVie Therapeutics Enters into Licensing Agreement with Sigma-Tau Industrie 23
CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau 24
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 26
Sigma-Tau Pharma Enters into Licensing Agreement with Crosscare for Colief 27
Lees Pharma HK Enters into Licensing Agreement with Sigma-Tau Industrie Farmaceutiche Riunite 28
Asset Transactions 29
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 29
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 30
Acquisition 32
Sigma-Tau May Sell Sigma-Tau Pharma 32
Alfa Wassermann Acquires Promefarm 33
Alfa Wassermann SpA - Key Competitors 34
Alfa Wassermann SpA - Key Employees 35
Alfa Wassermann SpA - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List Of Tables

List of Tables
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Key Facts 2
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfa Wassermann SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfa Wassermann SpA, Deals By Therapy Area, 2012 to YTD 2018 8
Alfa Wassermann SpA, Medical Devices Deals, 2012 to YTD 2018 10
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 13
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 15
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 16
European Institute of Oncology Enters Into Co-Development Agreement With Sigma Tau Industrie 17
Theravance Enters Into Co-Development Agreement With Alfa Wassermann For Velusetrag 18
a V.I. Pharma Enters into Distribution Agreement with Sigma-Tau for Eurartesim 19
Ezose Sciences Enters Into R&D Agreement With Sigma-Tau Industrie Farmaceutiche 20
CVie Therapeutics to Enter into Licensing Agreement with RostaQuo 21
CVie Therapeutics Enters into Licensing Agreement with Sigma-Tau Industrie 23
CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau 24
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 26
Sigma-Tau Pharma Enters into Licensing Agreement with Crosscare for Colief 27
Lees Pharma HK Enters into Licensing Agreement with Sigma-Tau Industrie Farmaceutiche Riunite 28
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 29
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 30
Sigma-Tau May Sell Sigma-Tau Pharma 32
Alfa Wassermann Acquires Promefarm 33
Alfa Wassermann SpA, Key Competitors 34
Alfa Wassermann SpA, Key Employees 35
Alfa Wassermann SpA, Other Locations 36
Alfa Wassermann SpA, Subsidiaries 36

List Of Figures

List of Figures
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alfa Wassermann SpA, Medical Devices Deals, 2012 to YTD 2018 10

In this report, the United States Darbepoetin Alfa market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025,

View Report

In this report, the global Alfalfa Hay market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing

View Report

The global Aalfalfa Concentrate market is valued at XX million USD in 2017 and is expected to reach XX million USD by the end of 2025, growing at a CAGR

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports